Sanese, Paola
De Marco, Katia
Lepore Signorile, Martina
La Rocca, Francesca
Forte, Giovanna
Latrofa, Marialaura
Fasano, Candida
Disciglio, Vittoria
Di Nicola, Elisabetta
Pantaleo, Antonino
Bianco, Giusy
Spilotro, Vito
Ferroni, Claudia
Tubertini, Matilde
Labarile, Nicoletta
De Marinis, Lucia
Armentano, Raffaele
Gigante, Gianluigi
Lantone, Valerio
Lantone, Giuliano
Naldi, Marina
Bartolini, Manuela
Varchi, Greta
Del Rio, Alberto
Grossi, Valentina
Simone, Cristiano
Funding for this research was provided by:
Ministero della Salute (SG-2019-12371540, Ricerca Corrente 2021-2023, Ricerca Corrente 2023-2025, Ricerca Corrente 2022-2024, Ricerca Corrente 2022-2024, Ricerca Corrente 2024-2026, Ricerca Corrente 2024-2026)
Associazione Italiana per la Ricerca sul Cancro (IG-23794, IG 19172, ID26678-2021)
Article History
Received: 13 February 2024
Accepted: 21 May 2024
First Online: 30 May 2024
Declarations
:
: The study was conducted in accordance with the ethical standards of the Institutional Committee on Human Experimentation after informed consent (Ethics Committee name: Comitato Etico Istituto tumori “Giovanni.Paolo II”, Istituto di ricovero e cura a carattere scientifico, viale Orazio Flacco, 65–70124, Bari; approval code: Prot. n. 379/C.E.; approval date: 16 September 2020). The procedures involving animals were conducted in conformity with the institutional guidelines that comply with national and international laws and policies (Authorization number: 870/2021-PR). Experiment carried out by Biogem Animal House was assessed under Ministerial Authorization (nr: 08/2023-UT).
: The entire group of writers has unanimously agreed to publish this document.
: International patent application n. PCT/IB2023/060121. Filing date 13.10.2022. Publication date 18/04/2024, n. WO2024/079603. Patent applicant: ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO "SAVERIO DE BELLIS". Name of inventors: Alberto Del Rio and Cristiano Simone. Specific aspect of the manuscript covered in the patent application: combination of EM127 and CHTs that are commonly used for CRC treatment (oxaliplatin, 5-fluorouracil, irinotecan). All other authors declare no competing interests.